{"protocolSection":{"identificationModule":{"nctId":"NCT00606021","orgStudyIdInfo":{"id":"11839"},"secondaryIdInfos":[{"id":"H3E-EZ-S114","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study Comparing of Two Different Chemotherapy Regimens, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer","officialTitle":"A Randomized Phase 2 Study Comparing Pemetrexed Plus Best Supportive Care With Best Supportive Care as Maintenance, Following First-Line Treatment With Pemetrexed-Cisplatin, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2011-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-01"},"primaryCompletionDateStruct":{"date":"2010-12","type":"ACTUAL"},"completionDateStruct":{"date":"2010-12","type":"ACTUAL"},"studyFirstSubmitDate":"2008-01-17","studyFirstSubmitQcDate":"2008-01-31","studyFirstPostDateStruct":{"date":"2008-02-01","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-10-03","resultsFirstSubmitQcDate":"2011-11-21","resultsFirstPostDateStruct":{"date":"2011-12-26","type":"ESTIMATED"},"lastUpdateSubmitDate":"2011-11-21","lastUpdatePostDateStruct":{"date":"2011-12-26","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This is a multicenter, open-label, randomized, two-arm Phase 2 study comparing pemetrexed plus best supportive care with best supportive care alone as maintenance therapy following first-line treatment with a pemetrexed-cisplatin combination in patients with advanced non-squamous non-small cell lung cancer.\n\nA total of approximately 100 patients are planned to be enrolled, and following completion of four cycles of pemetrexed-cisplatin (Induction Phase) those patients in which disease progression has not occurred will be randomized in a 2:1 ratio to one of two treatment arms (Maintenance Phase): Arm A (pemetrexed plus best supportive care) or Arm B (best supportive care alone)."},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":106,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"A: Pemetrexed + Best Supportive Care","type":"EXPERIMENTAL","description":"Pemetrexed: 500 milligrams per square meter (mg/m²) , intravenous (IV), Day 1 of each 21-day cycle for 6 cycles\n\nBest Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.","interventionNames":["Drug: pemetrexed","Drug: Best Supportive Care"]},{"label":"B: Best Supportive Care","type":"ACTIVE_COMPARATOR","description":"Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.","interventionNames":["Drug: Best Supportive Care"]}],"interventions":[{"type":"DRUG","name":"pemetrexed","description":"500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles","armGroupLabels":["A: Pemetrexed + Best Supportive Care"],"otherNames":["Alimta","LY231514"]},{"type":"DRUG","name":"Best Supportive Care","description":"Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.","armGroupLabels":["A: Pemetrexed + Best Supportive Care","B: Best Supportive Care"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival During Maintenance Phase","description":"Progression free survival is defined as the time from randomization until the date of progression of disease (PD) or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD is ≥20% increase in sum of longest diameter of target lesions. PD in maintenance phase uses the last lesion assessment prior to randomization as the baseline assessment.","timeFrame":"Randomization to progression of disease (PD) or date of death from any cause up to 30.9 months"}],"secondaryOutcomes":[{"measure":"Progression Free Survival During Overall Period (Induction Phase [IP] + Maintenance Phase [MP])","description":"Progression-free survival in overall period is defined as the time from the date of first dose of study drug during IP until the date of PD or death from any cause. PD was determined using RECIST criteria. PD is ≥20% increase in sum of longest diameter of target lesions. PD in overall period uses the screening lesion assessment prior to the induction phase as the baseline assessment.","timeFrame":"First dose of study drug during IP to PD or date of death from any cause up to 33.6 months"},{"measure":"Overall Survival During Maintenance Phase","description":"Overall survival in maintenance phase is defined as the time from randomization to death. Participants who were alive were censored at the last contact.","timeFrame":"Randomization to PD or date of death from any cause up to 31.3 months"},{"measure":"Overall Survival During Overall Period (IP + MP)","description":"Overall survival in overall period is defined as the time from first dose of study drug during IP to death. Participants who were alive were censored at the last contact.","timeFrame":"First dose of study drug during IP to PD or date of death from any cause up to 34.1 months"},{"measure":"Number of Participants With Adverse Events (AEs) During Overall Period","description":"The list of serious adverse events (SAEs) and other non-serious adverse events (AEs) are in Adverse Events Section.","timeFrame":"First dose of study drug during IP through overall study completion (up to 34.3) months"},{"measure":"Tumor Response Rate and Disease Control Rate After Induction Phase (IP)","description":"Tumor response rate (%) is the number of responders (participants with best response of CR or PR) divided by the number of participants qualified for tumor response according to RECIST criteria multiplied by 100. Disease control rate is percentage of participants with a best response of stable disease \\[SD\\], PR, or CR. CR=disappearance of all target lesions; PR=30% decrease in sum of longest diameter of target lesions; PD is≥20% increase in sum of longest diameter of target lesions. SD= neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.","timeFrame":"Randomization to measured PD up to 31.4 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. You must be at least 18 years old\n2. You must have been diagnosed with non-squamous non-small cell lung cancer (NSCLC)\n3. You must have had no prior systemic anticancer therapy for lung cancer\n4. You must live close enough to the study doctor to be able to visit regularly for follow up\n5. You must have signed informed consent form indicating your willingness to take part in this study\n6. Your laboratory and medical history and tests must meet study requirements\n\nExclusion criteria:\n\n1. Treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry\n2. Prior radiotherapy and surgery should be completed at least 4 weeks prior to initiation of treatment\n3. Serious concomitant systemic disorder (e.g., active infection including human immunodeficiency virus, or unstable cardiovascular disease)\n4. Prior malignancy other than NSCLC, carcinoma in situ of the cervix, or nonmelanoma skin cancer unless treated at least 5 years previously with no subsequent evidence of recurrence\n5. Brain metastasis\n6. Presence of clinically significant (by physical exam) third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry\n7. Significant weight loss (greater than 10%), over the previous 6 weeks before study entry\n8. Concurrent administration of any other antitumor therapy\n9. Inability to interrupt aspirin or other non-steroidal anti-inflammatory agents for a 5-day period (8-day period for long-acting agents such as piroxicam)\n10. Inability or unwillingness to take folic acid, dexamethasone (or equivalent) or vitamin B12 supplementation\n11. Pregnancy or breast-feeding\n12. You are allergic to pemetrexed","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9am to 5pm Eastern Time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Asyut","zip":"0000","country":"Egypt","geoPoint":{"lat":27.18096,"lon":31.18368}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cairo","zip":"11372","country":"Egypt","geoPoint":{"lat":30.06263,"lon":31.24967}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mounofia","zip":"32514","country":"Egypt"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Beirut","country":"Lebanon","geoPoint":{"lat":33.89332,"lon":35.50157}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Riyadh","zip":"11211","country":"Saudi Arabia","geoPoint":{"lat":24.68773,"lon":46.72185}}]},"referencesModule":{"references":[{"pmid":"23006447","type":"DERIVED","citation":"Mubarak N, Gaafar R, Shehata S, Hashem T, Abigeres D, Azim HA, El-Husseiny G, Al-Husaini H, Liu Z. A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer. BMC Cancer. 2012 Sep 24;12:423. doi: 10.1186/1471-2407-12-423."}],"seeAlsoLinks":[{"label":"Lilly Clinical Trial Registry","url":"http://www.lillytrials.com"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Induction phase (IP) is from first dose of study drug until randomization and entering to maintenance phase (MP) or discontinuation from treatment during IP. 106 participants were treated during IP. MP is from randomization to discontinuation from treatment. Overall period is IP+MP, whereas overall study is MP only.","groups":[{"id":"FG000","title":"Pemetrexed Plus Cisplatin (Induction Phase)","description":"Pemetrexed, 500 milligrams per square meter (mg/m²), intravenous (IV) followed by Cisplatin, IV, 75 mg/m² on Day 1 of each 21-day cycle for 4 cycles"},{"id":"FG001","title":"Pemetrexed Plus Best Supportive Care (Maintenance Phase)","description":"Pemetrexed: 500 (mg/m²), IV, Day 1 of each 21-day cycle for 6 cycles\n\nBest Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."},{"id":"FG002","title":"Best Supportive Care (Maintenance Phase)","description":"Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."}],"periods":[{"title":"Induction Phase","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"106"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"87"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"73"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]},{"title":"Maintenance Phase","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"28"},{"groupId":"FG002","numSubjects":"27"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"10"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"23"},{"groupId":"FG002","numSubjects":"17"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"17"},{"groupId":"FG002","numSubjects":"15"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Pemetrexed Plus Best Supportive Care (Maintenance Phase)","description":"Pemetrexed: 500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles\n\nBest Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."},{"id":"BG001","title":"Best Supportive Care (Maintenance Phase)","description":"Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"55"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"57.4","spread":"12.52"},{"groupId":"BG001","value":"62.9","spread":"9.97"},{"groupId":"BG002","value":"60.1","spread":"11.57"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"18"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"37"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"52"}]}]},{"title":"African","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Egypt","categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"43"}]}]},{"title":"Saudi Arabia","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]},{"title":"Lebanon","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"11"}]}]}]},{"title":"Pathological Diagnosis","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Mixed Cell Carcinoma, Lung","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}]},{"title":"Large Cells Lung Carcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"13"}]}]},{"title":"Adenocarcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"40"}]}]}]},{"title":"Stage of Disease at The Time of Entry into This Study","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Stage III B - Locally advanced","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"19"}]}]},{"title":"Stage IV - Metastasized","categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"36"}]}]}]},{"title":"Eastern Cooperative Oncology Group (ECOG) Performance Status at randomization of maintenance phase","description":"Classifies participants according to their functional impairment. Scores range from 0 (Fully Active) to 5 (Death).","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"0 - Fully active","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"14"}]}]},{"title":"1 - Ambulatory, restricted strenuous activity","categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"37"}]}]},{"title":"2 - Ambulatory, unable to carry out work activity","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]}]}]},{"title":"Lesion Response to induction phase","description":"The lesions response is classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. Complete Response (CR): disappearance of all target lesions; Partial Response: (PR) ≥30% decrease in sum of longest diameter of target lesions. Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD: ≥20% increase in sum of longest diameter of target lesions).","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Complete Response (CR)","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]},{"title":"Partial Response (PR)","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"21"}]}]},{"title":"Stable Disease (SD)","categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"30"}]}]},{"title":"Unknown","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival During Maintenance Phase","description":"Progression free survival is defined as the time from randomization until the date of progression of disease (PD) or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD is ≥20% increase in sum of longest diameter of target lesions. PD in maintenance phase uses the last lesion assessment prior to randomization as the baseline assessment.","populationDescription":"Participants who were randomized into maintenance phase and had measurable or evaluable lesions at baseline (last assessment before randomization) and post-baseline.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to progression of disease (PD) or date of death from any cause up to 30.9 months","groups":[{"id":"OG000","title":"Pemetrexed Plus Best Supportive Care (Maintenance Phase)","description":"Pemetrexed: 500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles\n\nBest Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."},{"id":"OG001","title":"Best Supportive Care (Maintenance Phase)","description":"Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","lowerLimit":"2.9","upperLimit":"6.1"},{"groupId":"OG001","value":"3.2","lowerLimit":"2.2","upperLimit":"4.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1815","pValueComment":"The significant level for the primary outcome measure of progression free survival during maintenance phase is one-sided 0.2.","statisticalMethod":"Regression, Cox","statisticalComment":"Stratified Cox regression model is used for hazard ratio estimate. Stratification factor: response status prior to randomization.","paramType":"Hazard Ratio (HR)","paramValue":"0.76","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.42","ciUpperLimit":"1.37"}]},{"type":"SECONDARY","title":"Progression Free Survival During Overall Period (Induction Phase [IP] + Maintenance Phase [MP])","description":"Progression-free survival in overall period is defined as the time from the date of first dose of study drug during IP until the date of PD or death from any cause. PD was determined using RECIST criteria. PD is ≥20% increase in sum of longest diameter of target lesions. PD in overall period uses the screening lesion assessment prior to the induction phase as the baseline assessment.","populationDescription":"Participants who took at least one dose of study drug during IP and had measurable or evaluable lesions at baseline (assessment before induction phase) and post baseline.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"First dose of study drug during IP to PD or date of death from any cause up to 33.6 months","groups":[{"id":"OG000","title":"Pemetrexed Plus Best Supportive Care (Maintenance Phase)","description":"Pemetrexed: 500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles\n\nBest Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."},{"id":"OG001","title":"Best Supportive Care (Maintenance Phase)","description":"Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","lowerLimit":"6.0","upperLimit":"8.3"},{"groupId":"OG001","value":"6.0","lowerLimit":"4.6","upperLimit":"6.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1233","pValueComment":"The significant level for the secondary outcome measure of progression free survival during overall period is one-sided 0.2.","statisticalMethod":"Regression, Cox","statisticalComment":"Stratified Cox regression model is used for hazard ratio estimate. Stratification factor: response status prior to randomization.","paramType":"Hazard Ratio (HR)","paramValue":"0.71","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.40","ciUpperLimit":"1.26"}]},{"type":"SECONDARY","title":"Overall Survival During Maintenance Phase","description":"Overall survival in maintenance phase is defined as the time from randomization to death. Participants who were alive were censored at the last contact.","populationDescription":"Participants who were randomized into maintenance phase and had measurable or evaluable lesions at baseline (last assessment before randomization) and post-baseline.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to PD or date of death from any cause up to 31.3 months","groups":[{"id":"OG000","title":"Pemetrexed Plus Best Supportive Care (Maintenance Phase)","description":"Pemetrexed: 500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles\n\nBest Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."},{"id":"OG001","title":"Best Supportive Care (Maintenance Phase)","description":"Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","lowerLimit":"5.6","upperLimit":"20.6"},{"groupId":"OG001","value":"11.8","lowerLimit":"6.3","upperLimit":"25.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.7239","pValueComment":"The significant level for the secondary outcome measure overall survival during maintenance period is two-sided 0.05.","statisticalMethod":"Regression, Cox","statisticalComment":"Stratified Cox regression model is used for hazard ratio estimate. Stratification factor: response status prior to randomization.","paramType":"Hazard Ratio (HR)","paramValue":"1.13","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.56","ciUpperLimit":"2.28"}]},{"type":"SECONDARY","title":"Overall Survival During Overall Period (IP + MP)","description":"Overall survival in overall period is defined as the time from first dose of study drug during IP to death. Participants who were alive were censored at the last contact.","populationDescription":"Participants who took at least one dose of study drug during IP and had measurable or evaluable lesions at baseline (assessment before induction phase) and post baseline.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"First dose of study drug during IP to PD or date of death from any cause up to 34.1 months","groups":[{"id":"OG000","title":"Pemetrexed Plus Best Supportive Care (Maintenance Phase)","description":"Pemetrexed: 500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles\n\nBest Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."},{"id":"OG001","title":"Best Supportive Care (Maintenance Phase)","description":"Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","lowerLimit":"8.4","upperLimit":"23.7"},{"groupId":"OG001","value":"16.4","lowerLimit":"9.1","upperLimit":"28.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6376","pValueComment":"The significant level for the secondary outcome measure overall survival during overall period is two-sided 0.05.","statisticalMethod":"Regression, Cox","statisticalComment":"Stratified Cox regression model is used for hazard ratio estimate. Stratification factor: response status prior to randomization.","paramType":"Hazard Ratio (HR)","paramValue":"1.18","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.59","ciUpperLimit":"2.38"}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs) During Overall Period","description":"The list of serious adverse events (SAEs) and other non-serious adverse events (AEs) are in Adverse Events Section.","populationDescription":"Participants who took at least one dose of study drug during IP, and randomized to maintenance phase.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"First dose of study drug during IP through overall study completion (up to 34.3) months","groups":[{"id":"OG000","title":"Pemetrexed Plus Best Supportive Care (Maintenance Phase)","description":"Pemetrexed: 500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles\n\nBest Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."},{"id":"OG001","title":"Best Supportive Care (Maintenance Phase)","description":"Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."},{"id":"OG002","title":"Pemetrexed Plus Cisplatin (Induction Phase)","description":"Pemetrexed, 500 milligrams per square meter (mg/m²), intravenous (IV) followed by Cisplatin, IV, 75 mg/m² on Day 1 of each 21-day cycle for 4 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"106"}]}],"classes":[{"title":"Adverse Events (AE)","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"74"}]}]},{"title":"Serious Adverse Events (SAE)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"13"}]}]}]},{"type":"SECONDARY","title":"Tumor Response Rate and Disease Control Rate After Induction Phase (IP)","description":"Tumor response rate (%) is the number of responders (participants with best response of CR or PR) divided by the number of participants qualified for tumor response according to RECIST criteria multiplied by 100. Disease control rate is percentage of participants with a best response of stable disease \\[SD\\], PR, or CR. CR=disappearance of all target lesions; PR=30% decrease in sum of longest diameter of target lesions; PD is≥20% increase in sum of longest diameter of target lesions. SD= neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.","populationDescription":"Participants who were randomized into maintenance phase and had measurable or evaluable lesions at baseline (last assessment before randomization) and post-baseline.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Randomization to measured PD up to 31.4 months","groups":[{"id":"OG000","title":"Pemetrexed Plus Best Supportive Care (Maintenance Phase)","description":"Pemetrexed: 500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles\n\nBest Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."},{"id":"OG001","title":"Best Supportive Care (Maintenance Phase)","description":"Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"}]}],"classes":[{"title":"Best Overall Response Rate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"12.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"12.8"}]}]},{"title":"CR","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"12.3"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"12.8"}]}]},{"title":"PR","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"12.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"12.8"}]}]},{"title":"SD","categories":[{"measurements":[{"groupId":"OG000","value":"57.1","lowerLimit":"37.2","upperLimit":"75.5"},{"groupId":"OG001","value":"44.4","lowerLimit":"25.5","upperLimit":"64.7"}]}]},{"title":"Disease Control Rate","categories":[{"measurements":[{"groupId":"OG000","value":"57.1","lowerLimit":"37.2","upperLimit":"75.5"},{"groupId":"OG001","value":"44.4","lowerLimit":"25.5","upperLimit":"64.7"}]}]},{"title":"PD","categories":[{"measurements":[{"groupId":"OG000","value":"32.1","lowerLimit":"15.9","upperLimit":"52.4"},{"groupId":"OG001","value":"37.0","lowerLimit":"19.4","upperLimit":"57.6"}]}]},{"title":"Early Death From Malignant Disease","categories":[{"measurements":[{"groupId":"OG000","value":"7.1","lowerLimit":"0.9","upperLimit":"23.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"12.8"}]}]},{"title":"Early Death From Toxicity","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"12.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"12.8"}]}]},{"title":"Early Death From other cause","categories":[{"measurements":[{"groupId":"OG000","value":"3.6","lowerLimit":"0.1","upperLimit":"18.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"12.8"}]}]},{"title":"Unknown","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"12.3"},{"groupId":"OG001","value":"18.5","lowerLimit":"6.3","upperLimit":"38.1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","description":"Adverse events include pre-existing conditions.","eventGroups":[{"id":"EG000","title":"Pemetrexed Plus Best Supportive Care - Maintenance Phase","description":"Pemetrexed: 500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.","seriousNumAffected":1,"seriousNumAtRisk":28,"otherNumAffected":15,"otherNumAtRisk":28},{"id":"EG001","title":"Best Supportive Care - Maintenance Phase","description":"Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.","seriousNumAffected":1,"seriousNumAtRisk":27,"otherNumAffected":16,"otherNumAtRisk":27},{"id":"EG002","title":"Pemetrexed + Cisplatin - Induction Phase","description":"Pemetrexed, 500 milligrams per square meter (mg/m²), intravenous (IV) followed by Cisplatin, IV, 75 mg/m² on Day 1 of each 21-day cycle for 4 cycles.","seriousNumAffected":13,"seriousNumAtRisk":106,"otherNumAffected":74,"otherNumAtRisk":106}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":106}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":106}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":106}]},{"term":"Deafness","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":106}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":106}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":106}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":106}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":106}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":106}]},{"term":"Altered state of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":106}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":106}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":106}]},{"term":"Diabetic ketoacidotic hyperglycaemic coma","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":106}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":106}]},{"term":"Ovarian cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":106}]},{"term":"Respiratory arrest","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":106}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":106}]},{"term":"Arterial thrombosis limb","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":106}]},{"term":"Circulatory collapse","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":106}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":28},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":27},{"groupId":"EG002","numEvents":16,"numAffected":14,"numAtRisk":106}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":106}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":3,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":16,"numAffected":11,"numAtRisk":106}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":106}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":10,"numAffected":8,"numAtRisk":106}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":20,"numAffected":15,"numAtRisk":106}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":65,"numAffected":35,"numAtRisk":106}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":28},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":27},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":106}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":28},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":27},{"groupId":"EG002","numEvents":30,"numAffected":25,"numAtRisk":106}]},{"term":"Hyperbilirubinaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":106}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":106}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":27},{"groupId":"EG002","numEvents":36,"numAffected":26,"numAtRisk":106}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":27},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":106}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":27},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":106}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":106}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":106}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":106}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":27},{"groupId":"EG002","numEvents":12,"numAffected":10,"numAtRisk":106}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":28},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":27},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":106}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":106}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Due to a mistake in the randomization parameters form, the randomization was actually implemented in the ratio of 1:1 instead of the planned ratio of 2:1."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}